
First allogeneic cancer immunotherapy hits market
On December 20th, the European Commission approved Tabelecleucel (EbvalloTM) as a monotherapy for the treatment of adult and paediatric patients who...

€72M from Novo´s REPAIR Impact Fund for Group B Streptococcus vaccines
Group B Streptococcus (GBS) colonises globally about 15-25% of women and can cause life-threatening infections in newborns during the first months of...

Evotec and Janssen team up in immunooncology
Hamburg-based Evotec SE has entered into a R&D and licencing agreement with Janssen Biotech, a J&J subsidiary to develop immune-based...

Partnering revitalized at the BioFit2022 – in Strasbourg and online
A biologist, a CEO, and a venture capitalist enter the BioFit2022 event...., while this may sound like the beginning of a great joke, it fits the...

Chong Kun Dang Pharm licences Synaffix ADC platform
Though the companies did not give any financial details, former licencing deals of Synaffix to global pharma companies such as Amgen or ranged...

Upping sustainability in pharma packaging
From glass vials, over cardboard applications, and biodegradable containers, on the PHARMAPACK Europe 2023 taking place on February 1st and 2nd in...

Novo Nordisk funds API manufacturing with €726m
Novo Nordisk’s latest expansion of R&D as well as production capacity is motivated by the need to generate more of its GLP-1 agonist semaglutide,...